Community-Acquired Pneumonia (CAP) Surveillance

Prospective, non-interventional, multi-center study. 7 investigative centers will involved in China. Around 560 CAP outpatients or inpatients will be screened until 56 M. pneumoniae isolates collected.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pneumonia Infections Lung Diseases Respiratory Tract Diseases Respiratory Tract Infections

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Many Locations, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Chinese adult (male or female) ≥18 years old
Outpatients or inpatients who suffer from CAP

Exclusion criteria

Treatment and study plan

No drug

Other

It's a surveillance

Primary outcomes

In vitro Minimal Inhibitory Concentration Detection

Time frame: Up to 27 months

Secondary outcomes

In vitro Gene Mutation Detection

Time frame: Up to 15 months

Sponsors and collaborators

Lead sponsor

Bayer

Industry

Registry information

Official study title

Community-Acquired Pneumonia (CAP) Mycoplasma Surveillance

Important dates

Study start: 2010
Primary completion: 2012
Study completion: 2013
First posted: Aug 15, 2011
Registry last updated: Nov 5, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed